Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


01 junio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I). 2-Year Clinical and Imaging Results. CME

Johannes Lammer, MDa; Marc Bosiers, MDb; Koen Deloose, MDc; Andrej Schmidt, MDd; Thomas Zeller, MDd; Florian Wolf, MDa; Wouter Lansink, MDe; Antoine Sauguet, MDf; Frank Vermassen, MD, PhDg; Geert Lauwers, MDe; Dierk Scheinert, MDc; Jeffrey J. Popma, MDh; Robert McGreevy, PhDi; Richard Rapoza, PhDi; Lewis B. Schwartz, MDi; Michael R. Jaff, DOj

Objectives: This is the first-in-human study of a drug-eluting bioresorbable vascular scaffold (BVS) for treatment of peripheral artery disease (PAD) involving the external iliac artery (EIA) and superficial femoral artery (SFA).

01 junio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Externally Delivered Focused Ultrasound for Renal Denervation

Petr Neuzil, MDa; John Ormiston, MDb; Todd J. Brinton, MDc; Zdenek Starek, MDd; Murray Esler, MDe; Omar Dawood, MDf; Thomas L. Anderson, PhDf; Michael Gertner, MDf; Rob Whitbourne, MD, PhDg; Roland E. Schmieder, MDh

Objectives: The aim of this study was to assess clinical safety and efficacy outcomes of renal denervation executed by an externally delivered, completely noninvasive focused therapeutic ultrasound device.

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery. 1-Year Results of the PACUBA Trial

Christian M. Kinstner, MDa; Johannes Lammer, MDa; Andrea Willfort-Ehringer, MDb; Wolfgang Matzek, MDa; Michael Gschwandtner, MDb; Domagoj Javor, MDa; Martin Funovics, MDa; Maria Schoder, MDa; Renate Koppensteiner, MDb; Christian Loewe, MDa; Robin Ristl, PhDc; Florian Wolf, MDa

Objectives: The hypothesis that paclitaxel-eluting balloon angioplasty provides higher 1-year patency rates in femoropopliteal artery in-stent restenosis compared with standard percutaneous transluminal angioplasty (PTA) was tested.

12 febrero 2016

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Hypertension. Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation

Roland E. Schmieder, MD*,1; Christian Ott, MD1; Axel Schmid, MD2; Stefanie Friedrich, MD1; Iris Kistner, MD1; Tilmann Ditting, MD1; Roland Veelken, MD1; Michael Uder, MD2; Stefan W. Toennes, MD3

Background: Adherence to medication has been repeatedly proposed to represent a major cause of treatment‐resistant hypertension (TRH); however, treatment decisions such as treating TRH with renal denervation depend on accurate judgment of adherence. We carefully analyzed adherence rates to medication before and after renal denervation and its effect on blood pressure (BP) control.

18 marzo 2016

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Epidemiology. Carotid Atherosclerosis and Cerebral Microbleeds: The Framingham Heart Study

José R. Romero, MD*,1; Sarah R. Preis, ScD4,8; Alexa Beiser, PhD1,4,8; Charles DeCarli, MD7; Ralph B. D´Agostino, PhD5,8; Philip A. Wolf, MD1,8; Ramachandran S. Vasan, MD2,3,8; Joseph F. Polak, MD6,8; Sudha Seshadri, MD1,8

Background: Carotid atherosclerosis is associated with subclinical ischemic cerebrovascular disease, but its role in hemorrhage‐prone small vessel disease—represented by cerebral microbleed (CMB)—is unclear, although vascular risk factors underlie both conditions. We hypothesized that persons with carotid atherosclerosis would have higher risk of CMB, particularly in deep regions.

03 abril 2016

JOURNAL OF THE AMERICAN HEART ASSOCIATION. Kidney in Cardiovascular Disease. Effects of Restoration of Blood Flow on the Development of Aortic Atherosclerosis in ApoE−/− Mice With Unilateral Renal Artery Stenosis

Alokkumar S. Pathak, MD1; Jianhua Huang, MD1; Mauricio Rojas, MD1; Taylor C. Bazemore, MD3; Ruihai Zhou, MD1,2; George A. Stouffer, MD*,1,2

Background: Chronic unilateral renal artery stenosis (RAS) causes accelerated atherosclerosis in apolipoprotein E–deficient (ApoE−/−) mice, but effects of restoration of renal blood flow on aortic atherosclerosis are unknown.

01 abril 2016

AMERICAN HEART JOURNAL. The LIBERTY study: Design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease

George L. Adams, MD, MHS, Jihad Mustapha, MD, William Gray, MD, Nick J. Hargus, PhD, Brad J. Martinsen, PhD, Gary Ansel, MD, Michael R. Jaff, DO

Background: Most peripheral artery disease (PAD) clinical device trials are supported by commercial manufacturers and designed for regulatory device approval, with extensive inclusion/exclusion criteria to support homogeneous patient populations. High-risk patients with advanced disease, including critical limb ischemia (CLI), are often excluded leading to difficulty in translating trial results into real-world clinical practice. As a result, physicians have no direct guidance regarding the use of endovascular devices. There is a need for objectively assessed studies to evaluate clinical, functional, and economic outcomes in PAD patient populations.

01 mayo 2016

AMERICAN HEART JOURNAL. Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial

Jeffrey S. Berger, MD, MS, Brian G. Katona, PharmD, W. Schuyler Jones, MD, Manesh R. Patel, MD, Lars Norgren, MD, PhD, Iris Baumgartner, MD, Juuso Blomster, MD, Kenneth W. Mahaffey, MD, Peter Held, MD, PhD, Marcus Millegård, MSc, Gretchen Heizer, MS, Craig Reist, PhD, F. Gerry Fowkes, MD, William R. Hiatt, MD

Background: Despite overwhelming data demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data in peripheral artery disease (PAD) are less compelling. Aspirin has modest evidence supporting a reduction in cardiovascular events in patients with PAD, whereas clopidogrel monotherapy may be more effective in PAD. Ticagrelor, a potent, reversibly binding P2Y12 receptor antagonist, is beneficial in patients with acute coronary syndrome and prior myocardial infarction. The EUCLID trial is designed to address the need for effective antiplatelet therapy in PAD to decrease the risk of cardiovascular events.

01 abril 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Drug-Coated Balloons for Complex Femoropopliteal Lesions. 2-Year Results of a Real-World Registry

Andrej Schmidt, MDa; Michael Piorkowski, MDb; Henrik Görner, MDa; Sabine Steiner, MD, MSca; Yvonne Bausback, MDa; Susanne Scheinert, MDa; Ursula Banning-Eichenseer, PhDa; Holger Staab, MDc; Daniela Branzan, MDc; Ramon L. Varcoe, MDd; Dierk Scheinert, MDa

Objectives: The authors sought to investigate the efficacy of a drug-coated balloon (DCB) for treatment of complex femoropopliteal lesions.

01 abril 2016

JACC: CARDIOVASCULAR INTERVENTIONS. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions

Osamu Iida, MDa; Mitsuyoshi Takahara, MD, PhDb,c; Yoshimitsu Soga, MD, PhDd; Keisuke Hirano, MDe; Yasutaka Yamauchi, MD, PhDf; Kan Zen, MD, PhDg; Daizo Kawasaki, MD, PhDh; Shinsuke Nanto, MD, PhDi; Hiroyoshi Yokoi, MDj; Masaaki Uematsu, MD, PhDa

Objectives: This study sought to investigate the characteristics of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation for femoropopliteal (FP) lesions, and to examine 1-year prognosis after repeat endovascular therapy (re-EVT) for these DES-ISR.

01 mayo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease. Evidence From the SFA-Long Study

Antonio Micari, MD, PhDa; Giuseppe Vadalà, MDa; Fausto Castriota, MDb; Armando Liso, MDc; Chiara Grattoni, MDb; Paolo Russo, MDd; Alfredo Marchese, MDe; Paolo Pantaleo, MDf; Giuseppe Roscitano, MDa; Bruno Mario Cesana, MDg; Alberto Cremonesi, MDb

Objectives: The aim of this study was to appraise 1-year outcomes after percutaneous treatment of long femoropopliteal artery disease using paclitaxel-coated balloons.

11 marzo 2016

CIRCULATION. Vascular Medicine. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. 5-Year Results of the Zilver PTX Randomized Trial

Michael D. Dake, MD; Gary M. Ansel, MD; Michael R. Jaff, DO; Takao Ohki, MD; Richard R. Saxon, MD; H. Bob Smouse, MD; Lindsay S. Machan, MD; Scott A. Snyder, PhD; Erin E. O’Leary, PhD; Anthony O. Ragheb, PhD; Thomas Zeller, MD; on behalf of the Zilver PTX Investigators

Background: This randomized controlled trial evaluated clinical durability of Zilver PTX, a paclitaxel-coated drug-eluting stent (DES), for femoropopliteal artery lesions. Outcomes compare primary DES versus percutaneous transluminal angioplasty (PTA), overall DES (primary and provisional) versus standard care (PTA and provisional Zilver bare metal stent [BMS]), and provisional DES versus provisional BMS.

08 septiembre 2015

CIRCULATION. Epidemiology and Prevention. Population-Based Study of Incidence, Risk Factors, Outcome, and Prognosis of Ischemic Peripheral Arterial Events

Dominic P.J. Howard, DPhil; Amitava Banerjee, DPhil; Jack F. Fairhead, MA; Linda Hands, FRCS; Louise E. Silver, DPhil; Peter M. Rothwell, FMedSci; on behalf of the Oxford Vascular Study

Background:There are few published data on the incidence and long-term outcomes of critical limb ischemia, acute limb ischemia, or acute visceral ischemia with which to inform health service planning, to monitor prevention, and to enable risk prediction.

14 octubre 2015

CIRCULATION. Vascular Medicine. Red Blood Cell Dysfunction Induced by High-Fat Diet. Potential Implications for Obesity-Related Atherosclerosis

Dusten Unruh, BS*; Ramprasad Srinivasan, PhD*; Tyler Benson, BA*; Stephen Haigh, BA; Danielle Coyle, MS; Neil Batra, BA; Ryan Keil, BS; Robert Sturm, BS; Victor Blanco, PhD; Mary Palascak, BA; Robert S. Franco, PhD; Wilson Tong, MD; Tapan Chatterjee, PhD; David Y. Hui, PhD; W. Sean Davidson, PhD; Bruce J. Aronow, PhD; Theodosia Kalfa, MD, PhD; David Manka, PhD; Abigail Peairs, PhD; Andra Blomkalns, MD; David J. Fulton, PhD; Julia E. Brittain, PhD; Neal L. Weintraub, MD*; Vladimir Y. Bogdanov, PhD*

Background: High-fat diet (HFD) promotes endothelial dysfunction and proinflammatory monocyte activation, which contribute to atherosclerosis in obesity. We investigated whether HFD also induces the dysfunction of red blood cells (RBCs), which serve as a reservoir for chemokines via binding to Duffy antigen receptor for chemokines (DARC).

05 noviembre 2014

CIRCULATION. Cardiovascular Surgery. Endovascular Treatment of Mycotic Aortic Aneurysms. A European Multicenter Study

Karl Sörelius, MD; Kevin Mani, MD, PhD; Martin Björck, MD, PhD; Petr Sedivy, MD, PhD; Carl-Magnus Wahlgren, MD, PhD; Peter Taylor, MA, MChir, FRCS; Rachel E. Clough, PhD, MRCS; Oliver Lyons, MRCS, PhD; Matt Thompson, MD, FRCS; Jack Brownrigg, MBChB, MRCS; Krassi Ivancev, MD, PhD; Meryl Davis, BSc, MBBS, FRCS; Michael P. Jenkins, BSc, MBBS, MS, FRCS, FEBVS; Usman Jaffer, BSc, MBBS, FRCS, MSc, PhD, PGCE, FHEA; Matt Bown, MD, FRCS; Zoran Rancic, MD, PhD; Dieter Mayer, MD; Jan Brunkwall, MD, PhD; Michael Gawenda, MD, PhD; Tilo Kölbel, MD, PhD; Elixène Jean-Baptiste, MD, PhD, FEBVS; Frans Moll, MD, PhD; Paul Berger, MD; Christos D. Liapis, MD, PhD; Konstantinos G. Moulakakis, MD, PhD, FEBVS; Marcus Langenskiöld, MD, PhD; Håkan Roos, MD; Thomas Larzon, MD, PhD; Artai Pirouzram, MD; Anders Wanhainen, MD, PhD; for the European MAA collaborators

Background: Mycotic aortic aneurysm (MAA) is a rare and life-threatening disease. The aim of this European multicenter collaboration was to study the durability of endovascular aortic repair (EVAR) of MAA, by assessing late infection–related complications and long-term survival.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.